Cellectis S.A. (EPA:ALCLS)
1.338
-0.010 (-0.74%)
May 20, 2025, 5:35 PM CET
Cellectis Revenue
Cellectis had revenue of $12.03M USD in the quarter ending March 31, 2025, with 85.12% growth. This brings the company's revenue in the last twelve months to $54.75M, up 351.27% year-over-year. In the year 2024, Cellectis had annual revenue of $49.22M with 435.37% growth.
Revenue (ttm)
$54.75M
Revenue Growth
+351.27%
P/S Ratio
1.91
Revenue / Employee
$246.61K
Employees
222
Market Cap
96.72M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 49.22M | 40.02M | 435.37% |
Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
Dec 31, 2020 | 59.56M | 36.57M | 159.09% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
EssilorLuxottica Société anonyme | 26.51B |
Sanofi | 45.17B |
Sartorius Stedim Biotech | 2.86B |
bioMérieux | 3.98B |
Eurofins Scientific SE | 6.95B |
Ipsen | 3.57B |
Virbac | 1.40B |
emeis Société anonyme | 5.64B |
Cellectis News
- 5 days ago - Cellectis: Partnerships And Promised Data In 2025 Continue To Justify The Buy - Seeking Alpha
- 8 days ago - Cellectis Non-GAAP EPS of -$0.17, revenue of $12M misses by $1.83M - Seeking Alpha
- 8 days ago - Cellectis Reports Financial Results for the First Quarter 2025 - GlobeNewsWire
- 11 days ago - Cellectis Q1 2025 Earnings Preview - Seeking Alpha
- 14 days ago - Cellectis to Report First Quarter Financial Results on May 12, 2025 - GlobeNewsWire
- 22 days ago - Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting - GlobeNewsWire
- 2 months ago - Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga